Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.OCGN · Entity 5550 | Director | June 09, 2023 | June 09, 2023 |
| Traws Pharma, Inc.ONTX · Entity 8032 | Director · Chief Executive Officer | July 26, 2018 | July 30, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date June 09, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2033-06-09 | Direct | 112,205 |
Reported balance
After 2023-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-09 · Grant · Acquired 112,205 · Balance 112,205 F1: The option vests upon the earlier of (a) June 9, 2024 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests upon the earlier of (a) June 9, 2024 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.
Traws Pharma, Inc.
Report date July 26, 2018 · Filed July 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2028-07-26 | Direct | 1,065,600 |
Reported balance
After 2018-07-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-26 · Grant · Acquired 1,065,600 · Balance 1,065,600 F1: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 9, 2023 21:26 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 112,205 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001104659-23-070023 · tm2318370-3_4seq1.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,205 Underlying: Common Stock · 112,205 shares Expires 2033-06-09 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 9, 2024 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:06 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001062993-22-020658 · form4.xml · derivative · entry 3 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options, initially representing a right to purchase 54,000 shares, vest and become exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with Ocugen, Inc. on the applicable vesting dates. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:06 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 4,500 | $1.83 | $8,235.00 |
DisclosureSEC source: 0001062993-22-020658 · form4.xml · nonDerivative · entry 2 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:06 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 4,500 | $0.51 | $2,295.00 |
DisclosureSEC source: 0001062993-22-020658 · form4.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:19 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001062993-22-016559 · form4.xml · derivative · entry 3 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 7,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options, initially representing a right to purchase 54,000 shares, vest and become exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:19 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 7,500 | $2.57 | $19,275.00 |
DisclosureSEC source: 0001062993-22-016559 · form4.xml · nonDerivative · entry 2 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.56 to $2.61. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:19 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 7,500 | $0.51 | $3,825.00 |
DisclosureSEC source: 0001062993-22-016559 · form4.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 00:57 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 140,091 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001062993-22-014510 · form4.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,091 Underlying: Common Stock · 140,091 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 7, 2023 and (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001062993-22-010494 · form4.xml · derivative · entry 3 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 7,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options, initially representing a right to purchase 54,000 shares, vest and become exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 7,500 | $2.83 | $21,225.00 |
DisclosureSEC source: 0001062993-22-010494 · form4.xml · nonDerivative · entry 2 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.79 to $2.89. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:03 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 7,500 | $0.51 | $3,825.00 |
DisclosureSEC source: 0001062993-22-010494 · form4.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:33 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001062993-22-001294 · form4.xml · derivative · entry 3 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 7,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options, initially representing a right to purchase 54,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:33 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 7,500 | $4.07 | $30,525.00 |
DisclosureSEC source: 0001062993-22-001294 · form4.xml · nonDerivative · entry 2 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.02 to $4.09. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:33 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 7,500 | $0.51 | $3,825.00 |
DisclosureSEC source: 0001062993-22-001294 · form4.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 02:23 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 16,335 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001104659-21-151342 · tm2135818-4_4seq1.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,335 Underlying: Common Stock · 16,335 shares Expires 2031-12-16 F1 · derivative.exercise_date: The option vests monthly in equal installments over three years commencing on January 16, 2022, subject to continued service with Ocugen, Inc. on the applicable vesting dates. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 22:56 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001879785-21-000009 · edgar.xml · derivative · entry 3 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 7,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, initially representing a right to purchase 54,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 22:56 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 7,500 | $8.13 | $60,975.00 |
DisclosureSEC source: 0001879785-21-000009 · edgar.xml · nonDerivative · entry 2 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.10 to $8.14. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 22:56 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 7,500 | $0.51 | $3,825.00 |
DisclosureSEC source: 0001879785-21-000009 · edgar.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:04 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-21-000636 · edgar.xml · derivative · entry 3 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 7,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vest monthly in equal installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:04 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 7,500 | $6.40 | $48,000.00 |
DisclosureSEC source: 0001192482-21-000636 · edgar.xml · nonDerivative · entry 2 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.38 to $6.45. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:04 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 7,500 | $0.51 | $3,825.00 |
DisclosureSEC source: 0001192482-21-000636 · edgar.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:16 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-21-000346 · edgar.xml · derivative · entry 3 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 7,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested monthly in equal installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:16 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 7,500 | $5.33 | $39,975.00 |
DisclosureSEC source: 0001192482-21-000346 · edgar.xml · nonDerivative · entry 2 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.29 to $5.37. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:16 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 7,500 | $0.51 | $3,825.00 |
DisclosureSEC source: 0001192482-21-000346 · edgar.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 22:43 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001192482-21-000020 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2031-01-01 F1 · derivative.exercise_date: The option vests monthly in equal installments over three years commencing on February 1, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 01:17 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOptions (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000017 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The options vest monthly in equal installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 21:25 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 1,065,600 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001179110-18-010009 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,065,600 Underlying: Common Stock · 1,065,600 shares Expires 2028-07-26 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 22:26 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 73,220 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001179110-18-002981 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,220 Underlying: Common Stock · 73,220 shares Expires 2028-02-23 F1 · derivative.exercise_date: This option grant was made in lieu of cash payment for a portion of Dr. Kumar's year-end bonus. The options vest immediately. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:54 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 64,885 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001179110-18-000604 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,885 Underlying: Common Stock · 64,885 shares Expires 2028-01-03 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:03 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 23,810 | $2.10 | $50,001.00 |
DisclosureSEC source: 0001179110-17-006246 · edgar.xml · nonDerivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,227 F1 · ownership.direct: 37,510 shares are held by the Ramesh Kumar 2012 Trust, of which the reporting person is a trustee. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 18:32 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 44,027 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001179110-17-001043 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,027 Underlying: Common Stock · 44,027 shares Expires 2027-01-17 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:34 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 12,673 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001179110-16-033197 · edgar.xml · derivative · entry 1 Kumar Ramesh · CIK 0001580074 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,673 Underlying: Common Stock · 12,673 shares Expires 2026-12-15 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.